Hiroaki Nagano

18.4k total citations · 2 hit papers
451 papers, 13.1k citations indexed

About

Hiroaki Nagano is a scholar working on Surgery, Oncology and Hepatology. According to data from OpenAlex, Hiroaki Nagano has authored 451 papers receiving a total of 13.1k indexed citations (citations by other indexed papers that have themselves been cited), including 183 papers in Surgery, 176 papers in Oncology and 145 papers in Hepatology. Recurrent topics in Hiroaki Nagano's work include Hepatocellular Carcinoma Treatment and Prognosis (108 papers), Pancreatic and Hepatic Oncology Research (80 papers) and Cholangiocarcinoma and Gallbladder Cancer Studies (75 papers). Hiroaki Nagano is often cited by papers focused on Hepatocellular Carcinoma Treatment and Prognosis (108 papers), Pancreatic and Hepatic Oncology Research (80 papers) and Cholangiocarcinoma and Gallbladder Cancer Studies (75 papers). Hiroaki Nagano collaborates with scholars based in Japan, United States and China. Hiroaki Nagano's co-authors include Yuichiro� Doki, Koji Umeshita, Morito Monden, Masaki Mori, Shigeru Marubashi, Hiroshi Wada, Hidetoshi Eguchi, Keizo Dono, Masato Sakon and Shogo Kobayashi and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Biological Chemistry and Journal of Clinical Investigation.

In The Last Decade

Hiroaki Nagano

421 papers receiving 12.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Reprogramming of Mouse and Human Cells to Pluripotency Using Mature MicroRNAs

2011 574 citations Hideshi Ishii, Hiroaki Nagano et al. profile →
CD13 is a therapeutic target in human liver cancer stem cells

2010 501 citations Naotsugu Haraguchi, Hideshi Ishii et al. Journal of Clinical Investigation profile →

Peers

Countries citing papers authored by Hiroaki Nagano

Since Specialization

Citations

This map shows the geographic impact of Hiroaki Nagano's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hiroaki Nagano with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hiroaki Nagano more than expected).

Fields of papers citing papers by Hiroaki Nagano

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hiroaki Nagano. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hiroaki Nagano. The network helps show where Hiroaki Nagano may publish in the future.

Co-authorship network of co-authors of Hiroaki Nagano

This figure shows the co-authorship network connecting the top 25 collaborators of Hiroaki Nagano. A scholar is included among the top collaborators of Hiroaki Nagano based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hiroaki Nagano. Hiroaki Nagano is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Phase 1/2 study of liposomal irinotecan plus S-1 for metastatic pancreatic cancer refractory to gemcitabine-based treatment 2025 ·European Journal of Cancer ·Hiroshi Imaoka, Masafumi Ikeda, Masato Ozaka, (unknown), Naohiro Okano, Satoshi Shimizu, Hidetaka Tsumura, Yoshito Komatsu, (unknown), (unknown), Hiroaki Nagano, Terumasa Hisano, Mitsuhito Sasaki, Satoshi Kobayashi, Taito Fukushima, Shuichi Mitsunaga, Takaaki Furukawa, Satoshi Hamauchi, Makoto Ueno, Junji Furuse	0
2	Electron density derived from dual-energy CT for predicting thrombolytic therapeutic efficacy in patients with pulmonary embolism 2025 ·Japanese Journal of Radiology ·Hiroaki Nagano, Koji Takumi, (unknown), (unknown), Masatoyo Nakajo, Kiyohisa Kamimura, Masanori Nakajo, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Takashi Yoshiura	0
3	Prognostic significance of lymph node metastasis in pancreatic tail cancer: A multicenter retrospective study 2024 ·Annals of Gastroenterological Surgery ·Teijiro Hirashita, Naoki Ikenaga, Kohei Nakata, Masafumi Nakamura, Hiroshi Kurahara, Takao Ohtsuka, (unknown), Kazuyoshi Nishihara, Hiromitsu Hayashi, Shigeki Nakagawa, Takao Ide, Hirokazu Noshirο, (unknown), Susumu Eguchi, (unknown), Shiro Kohi, Atsushi Nanashima, Hiroaki Nagano, Mitsuhisa Takatsuki, Masafumi Inomata, (unknown)	1
4	Therapeutic Efficacy of IL7/CCL19-Expressing CAR-T Cells in Intractable Solid Tumor Models of Glioblastoma and Pancreatic Cancer 2024 ·Cancer Research Communications ·(unknown), Yukimi Sakoda, Keishi Adachi, (unknown), Masao Nakajima, Hiroyuki Yasuda, Hiroaki Nagano, Koji Tamada	8
5	Multiparametric approach with synthetic MR imaging for diagnosing salivary gland lesions 2024 ·Japanese Journal of Radiology ·Koji Takumi, (unknown), Hiroaki Nagano, Hiroto Hakamada, (unknown), Kiyohisa Kamimura, Masatoyo Nakajo, (unknown), (unknown), Takashi Yoshiura	3
6	Impact of conversion surgery after chemotherapy in patients with initially unresectable and recurrent biliary tract cancer 2023 ·Annals of Gastroenterological Surgery ·Ikuo Nakamura, Etsuro Hatano, Hideo Baba, Keiko Kamei, Hiroshi Wada, Junzo Shimizu, Masashi Kanai, Kenichi Yoshimura, Hiroaki Nagano, Tatsuya Ioka	6
7	Risk Factors of Complications from Central Bisectionectomy (H458) for Hepatocellular Carcinoma: A Multi-Institutional Single-Arm Analysis 2023 ·Cancers ·Atsushi Nanashima, Susumu Eguchi, Toru Hisaka, Yota Kawasaki, Yo‐ichi Yamashita, Takao Ide, Tamotsu Kuroki, Tomoharu Yoshizumi, Kenji Kitahara, Yuichi Endo, Tohru Utsunomiya, Masatoshi Kajiwara, Masahiko Sakoda, Kohji Okamoto, Hiroaki Nagano, Yuko Takami, Toru Beppu	2
8	Impact of the coronavirus disease 2019 pandemic on 20 representative surgical procedures in Japan based on the National Clinical Database: annual surveillance of 2021 by the Japan Surgical Society 2023 ·Surgery Today ·Taizo Hibi, Hiroyuki Yamamoto, Takahiro Miyoshi, Norihiko Ikeda, Akinobu Taketomi, Minoru Ōno, Masakazu Toi, Hisato Hara, Hiroaki Nagano, Yuko Kitagawa, Masaki Mori	4
9	A multicenter validation study for determining the condition of nonanatomical or minor anatomical hepatectomies satisfying technical difficulty of current high‐level hepatectomy certificated by the Japanese Society of Hepato‐Biliary‐Pancreatic Surgery 2023 ·Journal of Hepato-Biliary-Pancreatic Sciences ·Ryota Matsuki, Yoshihiro Sakamoto, Masao Yoshida, Satoshi Ogiso, Akihiko Soyama, (unknown), Yukio Tokumitsu, Susumu Eguchi, Kiyoshi Hasegawa, Hiroaki Nagano, Norihiro Kokudo, Etsuro Hatano	2
10	[A Case in Which FOLFOXIRI Was Useful as Preoperative Chemotherapy for Locally Advanced Rectal Cancer with Difficulty in Securing CRM]. 2022 ·PubMed ·(unknown), Nobuaki Suzuki, Shin Yoshida, Shinobu Tomochika, Hiroto Matsui, Yoshitaro Shindo, Yukio Tokumitsu, Yusaku Watanabe, Michihisa Iida, Shigeru Takeda, Tatsuya Ioka, Yoshinobu Hoshii, Hiroaki Nagano	0
11	Surgical shunt ligation for a congenital extrahepatic portosystemic shunt with pulmonary hypertension 2022 ·International Journal of Surgery Case Reports ·(unknown), Satoshi Matsukuma, (unknown), (unknown), Yasuhiro Ikeda, Hiroaki Nagano	1
12	Objective Response by mRECIST Is an Independent Prognostic Factor for Overall Survival in Hepatocellular Carcinoma Treated with Sorafenib in the SILIUS Trial 2019 ·Liver Cancer ·Masatoshi Kudo, Kazuomi Ueshima, Yasutaka Chiba, Sadahisa Ogasawara, Shuntaro Obi, Namiki Izumi, Hiroshi Aikata, Hiroaki Nagano, Etsuro Hatano, Yutaka Sasaki, Keisuke Hino, Takashi Kumada, Kazuhide Yamamoto, Yasuharu Imai, (unknown), Chikara Ogawa, Takuji Okusaka, Fumihiko Kanai, Yasuaki Arai	12
13	Stemness Is Enhanced in Gastric Cancer by a SET/PP2A/E2F1 Axis 2018 ·Molecular Cancer Research ·(unknown), (unknown), Shunya Tsuji, Kazuhiro Yoshimura, (unknown), Masashi Sakurai, Yusuke Sakai, Hiroko Takenouchi, Shigefumi Yoshino, Shoichi Hazama, Hiroaki Nagano, Hiroko Oshima, Masanobu Oshima, Michael P. Vitek, Tetsuya Matsuura, Yoshitaka Hippo, Tatsuya Usui, Takashi Ohama, Koichi Sato	39
14	Liver resection combined with inferior vena cava resection and reconstruction using artificial vascular graft: A literature review 2018 ·Annals of Gastroenterological Surgery ·Yoshito Tomimaru, Hidetoshi Eguchi, Hiroshi Wada, Yuichiro� Doki, Masaki Mori, Hiroaki Nagano	12
15	Establishment of a Novel Model for Anticancer Drug Resistance in Three‐Dimensional Primary Culture of Tumor Microenvironment 2016 ·Stem Cells International ·Tatsuya Usui, Masashi Sakurai, (unknown), (unknown), (unknown), Takashi Ohama, Nobuyuki Fujiwara, (unknown), Shunya Tsuji, Hideyuki Yamawaki, Shoichi Hazama, Hiroko Takenouchi, Masao Nakajima, Ryouichi Tsunedomi, Nobuaki Suzuki, Hiroaki Nagano, Koichi Sato	42
16	Selection criteria for hepatic resection in intermediate-stage (BCLC stage B) multiple hepatocellular carcinoma 2016 ·Surgery ·Hiroshi Wada, Hidetoshi Eguchi, Takehiro Noda, Hisataka Ogawa, Daisaku Yamada, Yoshito Tomimaru, Akira Tomokuni, Tadafumi Asaoka, Koichi Kawamoto, Kunihito Gotoh, Shigeru Marubashi, Koji Umeshita, Hiroaki Nagano, Yuichiro� Doki, Masaki Mori	58
17	Increased Immunogenicity of Tumor-Associated Antigen, Mucin 1, Engineered to Express α-Gal Epitopes: A Novel Approach to Immunotherapy in Pancreatic Cancer 2010 ·Cancer Research ·Takashi Deguchi, Masahiro Tanemura, Eiji Miyoshi, Hiroaki Nagano, (unknown), Yoshiaki Ohmura, Shogo Kobayashi, Shigeru Marubashi, Hidetoshi Eguchi, Yutaka Takeda, Toshinori Ito, Masaki Mori, Yuichiro� Doki, Yoshiki Sawa	50
18	CD13 is a therapeutic target in human liver cancer stem cells breakdown → 2010 ·Journal of Clinical Investigation ·Naotsugu Haraguchi, Hideshi Ishii, Koshi Mimori, Fumiaki Tanaka, Masahisa Ohkuma, Ho Min Kim, Hirofumi Akita, Daisuke Takiuchi, Hisanori Hatano, Hiroaki Nagano, Graham F. Barnard, Yuichiro� Doki, Masaki Mori	501
19	Differential Transcriptome Patterns for Acute Cellular Rejection in Recipients with Recurrent Hepatitis C After Liver Transplantation 2009 ·Liver Transplantation ·Tadafumi Asaoka, Tomoaki Kato, Shigeru Marubashi, Keizo Dono, Naoki Hama, Hidenori Takahashi, Shogo Kobayashi, Yutaka Takeda, Ichiro Takemasa, Hiroaki Nagano, Hideo Yoshida, Phillip Ruiz, Andreas G. Tzakis, Kenichi Matsubara, Morito Monden, Yuichiro� Doki, Masaki Mori	21
20	1983 ·The Nishinihon Journal of Dermatology ·Hiroaki Nagano, (unknown), (unknown), (unknown)	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact